TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.

  title={TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.},
  author={Ellen FM 't Hoen},
  journal={Chicago Journal of International Law},
  • E. Hoen
  • Published 2002
  • Business
  • Chicago Journal of International Law
I. INTRODUCTION Infectious diseases kill over 10 million people each year, more than 90 percent of whom are in the developing world.1 The leading causes of illness and death in Africa, Asia, and South America-regions that account for four-fifths of the world's population-are HIV/AIDS, respiratory infections, malaria, and tuberculosis. In particular, the magnitude of the AIDS crisis has drawn attention to the fact that millions of people in the developing world do not have access to the… Expand
Promising Trends in Access to Medicines
A survey of innovative strategies that aim at maximizing the potential of patents to facilitate the development and delivery of medicines against diseases, the burden of which falls principally on developing country populations. Expand
Patents, Access to Medicines and the Role of Non-Governmental Organisations
One-third of the world's population lacks access to the most basic essential drugs. For the destitute sick in the developing world, the price of medicines can determine whether they will be treated.Expand
Access to essential medicines in East Africa: A review of East Africa community and its member states approach to WTO-TRIPS public health flexibilities
When the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) was annexed to the Agreement Establishing the World Trade Organisation (WTO) in 1994, it set minimum standards forExpand
Patent right and access to medicine
The reasons for the lack of access to essential medicines are manifold, but in many cases the high price of drugs is a barrier to needed medicines. The unaffordable prices of drugs are often theExpand
The G8 and access to medicines: no more broken promises
On June 1 the G8 leaders will gather in Evian France where access to medicines is again at the top of the their agenda, but while several important commitments have been made to improve access to drugs few have been achieved and many have been forgotten. Expand
Breaking Bad Patents: Learning from HIV/AIDS to make COVID-19 treatments accessible
Three legal pathways for overriding and seizing patents on medicines are reviewed by describing cases in which they were employed to make antiretroviral drugs more accessible to people living with HIV. Expand
Challenges between Access to Medicine and Pharmaceutical Patents
From one hand, the interests of inventors and pharmaceutical firms, and from other hand, the right of access to medicine specially for the people who live in developing or law developed countries,Expand
Making medicines essential: The emergent centrality of pharmaceuticals in global health
Expanding access to pharmaceuticals has become one of the most visible aspects of twenty-first century global health practices, as evidenced by the moral urgency of antiretroviral rollout and theExpand
Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up.
The need for scaling-up is as urgent as ever: over two-thirds of the six million people in the developing world who are in urgent need of ARV therapy live in sub-Saharan Africa but less than 2% of these have access to this treatment. Expand
TRIPS and Public Health
The efforts of developing countries to use the mechanisms provided under TRIPS to promote public health have come under pressure from industrialised countries and multinational pharmaceuticalExpand